Table of Contents Author Guidelines Submit a Manuscript
International Journal of Vascular Medicine
Volume 2012, Article ID 162545, 7 pages
http://dx.doi.org/10.1155/2012/162545
Review Article

Effects of Statins on Cardiorenal Syndrome

1Department of Cardiovascular Medicine, The University of Tokushima Graduate School of Health Biosciences, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan
2Department of Medicine and Bioregulatory Sciences, The University of Tokushima Graduate School of Health Biosciences, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan
3Department of Pharmacology, The University of Tokushima Graduate School of Health Biosciences, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan
4Department of Medical Education, The University of Tokushima Graduate School of Health Biosciences, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan

Received 26 April 2012; Accepted 17 May 2012

Academic Editor: David Bishop-Bailey

Copyright © 2012 Shusuke Yagi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. G. Bongartz, M. J. Cramer, P. A. Doevendans, J. A. Joles, and B. Braam, “The severe cardiorenal syndrome: 'Guyton revisited',” European Heart Journal, vol. 26, no. 1, pp. 11–17, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Node, M. Fujita, M. Kitakaze, M. Hori, and J. K. Liao, “Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy,” Circulation, vol. 108, no. 7, pp. 839–843, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Wassmann, U. Laufs, K. Müller et al., “Cellular antioxidant effects of atorvastatin in vitro and in vivo,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 2, pp. 300–305, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Wolfrum, K. S. Jensen, and J. K. Liao, “Endothelium-dependent effects of statins,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 5, pp. 729–736, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. U. Laufs, F. Custodis, and M. Böhm, “HMG-CoA reductase inhibitors in chronic heart failure: potential mechanisms of benefit and risk,” Drugs, vol. 66, no. 2, pp. 145–154, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Ronco, P. McCullough, S. D. Anker et al., “Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative,” European Heart Journal, vol. 31, no. 6, pp. 703–711, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. A. S. Go, G. M. Chertow, D. Fan, C. E. McCulloch, and C. Y. Hsu, “Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization,” The New England Journal of Medicine, vol. 351, no. 13, pp. 1296–1305, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Merhaut and R. J. Trupp, “Cardiorenal dysfunction,” AACN Advanced Critical Care, vol. 21, no. 4, pp. 357–364, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. D. S. Keith, G. A. Nichols, C. M. Gullion, J. B. Brown, and D. H. Smith, “Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization,” Archives of Internal Medicine, vol. 164, no. 6, pp. 659–663, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. B. M. Wall, “Cardiorenal risk factors,” The American Journal of the Medical Sciences, vol. 340, pp. 25–29, 2010. View at Google Scholar
  11. H. L. Hillege, V. Fidler, G. F. H. Diercks et al., “Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population,” Circulation, vol. 106, no. 14, pp. 1777–1782, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. L. J. Ignarro, G. M. Buga, K. S. Wood, R. E. Byrns, and G. Chaudhuri, “Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 24, pp. 9265–9269, 1987. View at Google Scholar · View at Scopus
  13. U. C. Garg and A. Hassid, “Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells,” Journal of Clinical Investigation, vol. 83, no. 5, pp. 1774–1777, 1989. View at Google Scholar · View at Scopus
  14. P. Kubes, M. Suzuki, and D. N. Granger, “Nitric oxide: an endogenous modulator of leukocyte adhesion,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 11, pp. 4651–4655, 1991. View at Google Scholar · View at Scopus
  15. T. J. Anderson, I. T. Meredith, A. C. Yeung, B. Frei, A. P. Selwyn, and P. Ganz, “The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion,” The New England Journal of Medicine, vol. 332, no. 8, pp. 488–493, 1995. View at Publisher · View at Google Scholar · View at Scopus
  16. G. O'Driscoll, D. Green, and R. R. Taylor, “Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month,” Circulation, vol. 95, no. 5, pp. 1126–1131, 1997. View at Google Scholar · View at Scopus
  17. U. Laufs, V. la Fata, J. Plutzky, and J. K. Liao, “Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors,” Circulation, vol. 97, no. 12, pp. 1129–1135, 1998. View at Google Scholar · View at Scopus
  18. Y. Kureishi, Z. Luo, I. Shiojima et al., “The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals,” Nature Medicine, vol. 6, no. 9, pp. 1004–1010, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Endres, U. Laufs, Z. Huang et al., “Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 15, pp. 8880–8885, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Wolfrum, M. Grimm, M. Heidbreder et al., “Acute reduction of myocardial infarct size by a hydroxymethyl glutaryl coenzyme a reductase inhibitor is mediated by endothelial nitric oxide synthase,” Journal of Cardiovascular Pharmacology, vol. 41, no. 3, pp. 474–480, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. U. Forstermann and H. Li, “Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling,” vol. 164, pp. 213–223. View at Publisher · View at Google Scholar
  22. M. Takemoto, K. Node, H. Nakagami et al., “Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy,” Journal of Clinical Investigation, vol. 108, no. 10, pp. 1429–1437, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Wassmann, U. Laufs, A. T. Bäumer et al., “Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase,” Molecular Pharmacology, vol. 59, no. 3, pp. 646–654, 2001. View at Google Scholar · View at Scopus
  24. R. Ross, “The pathogenesis of atherosclerosis: a perspective for the 1990s,” Nature, vol. 362, no. 6423, pp. 801–809, 1993. View at Publisher · View at Google Scholar · View at Scopus
  25. R. S. Rosenson, “Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy,” American Journal of Cardiovascular Drugs, vol. 1, no. 6, pp. 411–420, 2001. View at Google Scholar · View at Scopus
  26. D. Tousoulis, C. Antoniades, E. Bosinakou et al., “Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure,” Atherosclerosis, vol. 178, no. 2, pp. 359–363, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Yamakuchi, J. J. M. Greer, S. J. Cameron et al., “HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size,” Circulation Research, vol. 96, no. 11, pp. 1185–1192, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. D. X. Bu, M. Tarrio, N. Grabie et al., “Statin-induced Kruppel-like factor 2 expression in human and mouse T cells reduces inflammatory and pathogenic responses,” Journal of Clinical Investigation, vol. 120, no. 6, pp. 1961–1970, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. M. F. Oliver, J. A. Heady, J. N. Morris, and J. Cooper, “W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the committee of principal investigators,” The Lancet, vol. 2, no. 8191, pp. 379–385, 1980. View at Google Scholar · View at Scopus
  30. “The lipid research clinics coronary primary prevention trial results II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering,” Journal of the American Medical Association, vol. 251, no. 3, pp. 365–374, 1984.
  31. M. H. Frick, O. Elo, and K. Haapa, “Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease,” The New England Journal of Medicine, vol. 317, no. 20, pp. 1237–1245, 1987. View at Google Scholar · View at Scopus
  32. J. Shepherd, S. M. Cobbe, I. Ford et al., “Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of scotland coronary prevention study group,” The New England Journal of Medicine, vol. 333, pp. 1301–1307, 1995. View at Google Scholar
  33. J. R. Downs, M. Clearfield, S. Weis et al., “Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS,” Journal of the American Medical Association, vol. 279, no. 20, pp. 1615–1622, 1998. View at Publisher · View at Google Scholar · View at Scopus
  34. H. Nakamura, K. Arakawa, H. Itakura et al., “Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial,” The Lancet, vol. 368, no. 9542, pp. 1155–1163, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. T. R. Pedersen, “Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the scandinavian simvastatin survival study (4s),” The Lancet, vol. 344, no. 8934, pp. 1383–1389, 1994. View at Google Scholar · View at Scopus
  36. “Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The long-term intervention with pravastatin in ischaemic disease (lipid) study group,” The New England Journal of Medicine, vol. 339, pp. 1349–1357, 1998.
  37. F. M. Sacks, M. A. Pfeffer, L. A. Moye et al., “The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators,” The New England Journal of Medicine, vol. 335, pp. 1001–1009, 1996. View at Publisher · View at Google Scholar
  38. S. E. Nissen, S. J. Nicholls, I. Sipahi et al., “Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial,” Journal of the American Medical Association, vol. 295, no. 13, pp. 1556–1565, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. S. E. Nissen, E. M. Tuzcu, P. Schoenhagen et al., “Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial,” Journal of the American Medical Association, vol. 291, no. 9, pp. 1071–1080, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. C. P. Cannon, E. Braunwald, C. H. McCabe et al., “Intensive versus moderate lipid lowering with statins after acute coronary syndromes,” The New England Journal of Medicine, vol. 350, no. 15, pp. 1495–1504, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. J. C. LaRosa, S. M. Grundy, D. D. Waters et al., “Intensive lipid lowering with atorvastatin in patients with stable coronary disease,” The New England Journal of Medicine, vol. 352, no. 14, pp. 1425–1435, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. U. Landmesser, N. Engberding, F. H. Bahlmann et al., “Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase,” Circulation, vol. 110, no. 14, pp. 1933–1939, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. L. Zhang, S. Zhang, H. Jiang, A. Sun, Y. Zou, and J. Ge, “Effects of statin treatment on cardiac function in patients with chronic heart failure: a meta-analysis of randomized controlled trials,” Clinical Cardiology, vol. 34, no. 2, pp. 117–123, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. J. Kjekshus, E. Apetrei, V. Barrios et al., “Rosuvastatin in older patients with systolic heart failure,” The New England Journal of Medicine, vol. 357, no. 22, pp. 2248–2261, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. L. Tavazzi, A. P. Maggioni, R. Marchioli et al., “Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomise, double-blind, placebo-controlled trial,” The Lancet, vol. 372, pp. 1231–1239, 2008. View at Publisher · View at Google Scholar
  46. J. J. V. McMurray, J. Kjekshus, L. Gullestad et al., “Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the controlled rosuvastatin multinational trial in heart failure (CORONA): a retrospective analysis,” Circulation, vol. 120, no. 22, pp. 2188–2196, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. J. G. F. Cleland, J. J. V. McMurray, J. Kjekshus et al., “Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from corona (controlled rosuvastatin multinational trial in heart failure),” Journal of the American College of Cardiology, vol. 54, no. 20, pp. 1850–1859, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. D. Mannheim, J. Herrmann, P. O. Bonetti, R. Lavi, L. O. Lerman, and A. Lerman, “Simvastatin preserves diastolic function in experimental hypercholesterolemia independently of its lipid lowering effect,” Atherosclerosis, vol. 216, no. 2, pp. 283–291, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. S. A. Chang, Y. J. Kim, H. W. Lee et al., “Effect of rosuvastatin on cardiac remodeling, function, and progression to heart failure in hypertensive heart with established left ventricular hypertrophy,” Hypertension, vol. 54, no. 3, pp. 591–597, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. Z. Xu, H. Okamoto, M. Akino, H. Onozuka, Y. Matsui, and H. Tsutsui, “Pravastatin attenuates left ventricular remodeling and diastolic dysfunction in angiotensin II-induced hypertensive mice,” Journal of Cardiovascular Pharmacology, vol. 51, no. 1, pp. 62–70, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. H. Fukuta, D. C. Sane, S. Brucks, and W. C. Little, “Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report,” Circulation, vol. 112, no. 3, pp. 357–363, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. F. Tehrani, R. Morrissey, A. Phan, C. Chien, and E. R. Schwarz, “Statin therapy in patients with diastolic heart failure,” Clinical Cardiology, vol. 33, no. 4, pp. E1–E5, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. P. Santangeli, G. Ferrante, G. Pelargonio et al., “Usefulness of statins in preventing atrial fibrillation in patients with permanent pacemaker: a systematic review,” Europace, vol. 12, no. 5, pp. 649–654, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. L. Fauchier, B. Pierre, A. de Labriolle, C. Grimard, N. Zannad, and D. Babuty, “Antiarrhythmic effect of statin therapy and atrial fibrillation. A meta-analysis of randomized controlled trials,” Journal of the American College of Cardiology, vol. 51, no. 8, pp. 828–835, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. S. D. Navaneethan, F. Pansini, V. Perkovic et al., “HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD007784, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. J. Shepherd, J. J. P. Kastelein, V. Bittner et al., “Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease. The TNT (treating to new targets) study,” Journal of the American College of Cardiology, vol. 51, no. 15, pp. 1448–1454, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. W. März, B. Genser, C. Drechsler et al., “Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 6, pp. 1316–1325, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. B. C. Fellstrom, A. G. Jardine, R. E. Schmieder et al., “Rosuvastatin and cardiovascular events in patients undergoing hemodialysis,” The New England Journal of Medicine, vol. 360, pp. 1395–1407, 2009. View at Publisher · View at Google Scholar
  59. W. F. Keane, “Lipids and the kidney,” Kidney International, vol. 46, no. 3, pp. 910–920, 1994. View at Google Scholar · View at Scopus
  60. R. Rubin, S. Silbiger, L. Sablay, and J. Neugarten, “Combined antihypertensive and lipid-lowering therapy in experimental glomerulonephritis,” Hypertension, vol. 23, no. 1, pp. 92–95, 1994. View at Google Scholar · View at Scopus
  61. M. Fujii, T. Inoguchi, Y. Maeda et al., “Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice,” Kidney International, vol. 72, no. 4, pp. 473–480, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. X. M. Liang, H. Otani, Q. Zhou et al., “Renal protective effects of pitavastatin on spontaneously hypercholesterolaemic Imai Rats,” Nephrology Dialysis Transplantation, vol. 22, no. 8, pp. 2156–2164, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. K. Douglas, P. G. O'Malley, and J. L. Jackson, “Meta-analysis: the effect of statins on albuminuria,” Annals of Internal Medicine, vol. 145, no. 2, pp. 117–124, 2006. View at Google Scholar · View at Scopus
  64. G. F. M. Strippoli, S. D. Navaneethan, D. W. Johnson et al., “Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials,” BMJ, vol. 336, no. 7645, pp. 645–651, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. J. Atthobari, A. H. Brantsma, R. T. Gansevoort et al., “The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study,” Nephrology Dialysis Transplantation, vol. 21, no. 11, pp. 3106–3114, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. P. Ruggenenti, A. Perna, M. Tonelli et al., “Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 11, pp. 1928–1938, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. V. G. Athyros, D. P. Mikhailidis, A. A. Papageorgiou et al., “The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study,” Journal of Clinical Pathology, vol. 57, no. 7, pp. 728–734, 2004. View at Publisher · View at Google Scholar · View at Scopus
  68. Y. Saito, “Pitavastatin: an overview,” Atherosclerosis Supplements, vol. 12, pp. 271–276, 2011. View at Publisher · View at Google Scholar
  69. A. M. Gotto Jr. and J. Moon, “Pitavastatin for the treatment of primary hyperlipidemia and mixed dyslipidemia,” Expert Review of Cardiovascular Therapy, vol. 8, no. 8, pp. 1079–1090, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. T. Nakamura, T. Sugaya, Y. Kawagoe, Y. Ueda, S. Osada, and H. Koide, “Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy,” Diabetes Care, vol. 28, no. 11, pp. 2728–2732, 2005. View at Publisher · View at Google Scholar · View at Scopus
  71. K. Arao, T. Yasu, T. Umemoto et al., “Effects of pitavastatin on fasting and postprandial endothelial function and blood rheology in patients with stable coronary artery disease,” Circulation Journal, vol. 73, no. 8, pp. 1523–1530, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. E. Kibayashi, M. Urakaze, C. Kobashi et al., “Inhibitory effect of pitavastatin (NK-104) on the C-reactive-protein- induced interleukin-8 production in human aortic endothelial cells,” Clinical Science, vol. 108, no. 6, pp. 515–521, 2005. View at Publisher · View at Google Scholar · View at Scopus
  73. T. Hiro, T. Kimura, T. Morimoto et al., “Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study),” Journal of the American College of Cardiology, vol. 54, no. 4, pp. 293–302, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. S. Morikawa, W. Takabe, C. Mataki et al., “The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells,” Journal of Atherosclerosis and Thrombosis, vol. 9, no. 4, pp. 178–183, 2002. View at Google Scholar · View at Scopus
  75. J. Wang, T. Tokoro, K. Matsui, S. Higa, and I. Kitajima, “Pitavastatin at low dose activates endothelial nitric oxide synthase through PI3K-AKT pathway in endothelial cells,” Life Sciences, vol. 76, no. 19, pp. 2257–2268, 2005. View at Publisher · View at Google Scholar · View at Scopus
  76. Y. Mizuguchi, Y. Oishi, H. Miyoshi, A. Iuchi, N. Nagase, and T. Oki, “Impact of statin therapy on left ventricular function and carotid arterial stiffness in patients with hypercholesterolemia,” Circulation Journal, vol. 72, no. 4, pp. 538–544, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. T. Aoyagi, F. Nakamura, T. Tomaru, and T. Toyo-Oka, “Beneficial effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardiac function in ischemic and nonischemic heart failure,” International Heart Journal, vol. 49, no. 1, pp. 49–58, 2008. View at Publisher · View at Google Scholar · View at Scopus
  78. K. Kimura, H. Shimano, K. Yokote, M. Urashima, and T. Teramoto, “Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease. Sub-analysis of the LIVALO effectiveness and safety (LIVES) study,” Journal of Atherosclerosis and Thrombosis, vol. 17, no. 6, pp. 601–609, 2010. View at Google Scholar · View at Scopus
  79. S. Yagi, K. I. Aihara, Y. Ikeda et al., “Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II-induced cardiovascular remodeling and renal insufficiency,” Circulation Research, vol. 102, no. 1, pp. 68–76, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. S. Yagi, M. Akaike, K. I. Aihara et al., “Endothelial nitric oxide synthase-independent protective action of statin against angiotensin ii-induced atrial remodeling via reduced oxidant injury,” Hypertension, vol. 55, no. 4, pp. 918–923, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. S. Yagi, M. Akaike, K. I. Aihara et al., “Effect of low-dose (1 mg/day) pitavastatin on left ventricular diastolic function and albuminuria in patients with hyperlipidemia,” American Journal of Cardiology, vol. 107, no. 11, pp. 1644–1649, 2011. View at Publisher · View at Google Scholar · View at Scopus